Document:

EXHIBIT 10.1
                                  ------------

        Advisory Agreements for John J. Majnarich and Michael C. Maloney

<PAGE>

                               ADVISORY AGREEMENT

Phage  Therapeutics,  Inc.  ("PhageTx" or the  "Company")  desires to engage the
advisory  services  ("Services")  of  John  J.  Majnarich,  PhD,  as an  advisor
("Advisor")  in the general field of  Preclinical  Testing.  Advisor  desires to
provide such Services to PhageTx.  By execution of this Advisory  Agreement (the
"Agreement"), and Advisor agrees to provide such Services in accordance with the
following terms and conditions:

1.  Services - At times  mutually  agreeable  to  Advisor  and  PhageTx,  and as
requested by PhageTX, Advisor will undertake the designated Services for one (1)
year,  commencing on the effective date of this Agreement (See Section 4 below).
It is expected  that Advisor  will  provide at least six (6) days of  cumulative
Services  during  the one (1)  year  period  of this  Agreement,  consisting  of
periodic  teleconferences,   electronic  mail,  written  communications,  direct
meetings, and the like, upon the prior agreement of Advisor and PhageTx.

2.  Compensation - In recognition  of Advisor's  contributions  to the Company's
product  development  efforts,  PhageTx  wishes  Advisor to  participate  int eh
Company's  future success by granting to Advisor an option to purchase shares of
stock in the Company in accord with the legal terms and  conditions of the Phage
Therapeutics, Inc. Stock Option Plan. The grant of options will be determined by
the Board of Directors,  which  functions as  Administrator  of the Stock Option
Plan, and will be executed through a separate Stock Option Agreement.

3. Independent Contractor - It is agreed that Advisor will have complete freedom
of action as to the details,  methods, and means of performing the Services.  It
is further  understood  that Advisor is retained and has contracted with PhageTx
only for the  purposes and to the extent set forth in this  Agreement,  and that
Advisor's  relation to PhageTx during the period of this Agreement shall be that
of an independent contractor,  and that Advisor shall be free to dispose of such
portion of his entire time, energy and skill as he is not obligated to devote to
PhageTx in such manner as he sees fit and to such person, firms, or corporations
as he deems  necessary,  so long as same does not create a conflict  of interest
between PhageTx and such other persons, firms or corporations. Advisor shall not
be considered  under the provisions of this Agreement or otherwise as having the
status of an employee of PhageTx,  nor shall  Advisor be entitled  hereafter  to
participate in any plans,  arrangements or  distributions by PhageTx relating to
any  pension,  deferred  compensation,   bonus,  stock  bonus,  hospitalization,
insurance  or  other  benefits  extended  to its  employees,  since  Advisor  is
performing the Services as an independent contractor.

4. Effective  Date,  Term,  Termination  and Extension - This Agreement  becomes
effective on January 1, 2001,  and will  continue in effect  until  December 31,
2001 (the first  twelve-month-period).  It is  provided,  however,  that  either
Advisor or PhageTx may terminate  this  Agreement at any time during its term by
giving at least one (1) month written notice to the other. At the sole option of
PhageTx,  this Agreement may be extended for one (1) or more consecutive  twelve
(12)-month  period(s),  under similar terms as are provided herein, by PhageTx's
providing to Advisor  written notice of its desire to continue the Agreement for
an  additional  term by at least two (2)  months  prior to the end of the twelve
(12)-month period in question.  However, certain of the terms may be modified by
mutual agreement of the parties.

5.  Inventions  - During  Advisor's  Service to PhageTx,  PhageTx  may  disclose
certain  confidential  information to Advisor and may ask Advisor to participate
in activities that may result in inventions  related to PhageTx's  technology or
business.  To the  extent  that  Advisor  is not  precluded  from  doing so by a
pre-existing employment contract or another agreement, where, as a direct result
of such  Services  to PhageTx,  Advisor  receives or is made aware of techn ical
information by a PhageTx employee, consultant, advisor or contractor that causes
Advisor to  conceive,  make or develop  any  inventions  relating  to  PhageTx's
bacteriophage  technology or products,  Advisor's  signature hereon notices that
Advisor agrees to: a) give notice of any such invention to PhageTx; b) assign to
PhagTx  all of  Advisor's  rights  therein,  in-so-far  as those  rights are not
subject to conditions of Advisor's current employment or another agreement; and,
c) execute any  documents  and otherwise  reasonably  cooperate  with PhageTx in
securing patents on such inventions.

6. Security - Advisor  shall,  during and  subsequent  to providing  Services to
PhageTx,  keep confidential and shall not use any technical or other proprietary
information  provided  by  PhageTx,  including  knowledge  of PhageTx  projects,
general  activities and proprietary  information not publicly disclosed relating
to PhageTx's  technology,  products and business  which Advisor may acquire as a
result of the Services or otherwise.  Advisor shall hold all such information in
strict  confidence and shall not use or disclose such information in any manner,
or cause same to be published  without  PhageTx's  prior written  consent.  This
obligation of confidence has been agreed to and is provided for between  Advisor
and PhageTx in a separate  Confidential  Disclosure  Agreement  executed by both
parties on 9 Feb. 2001.

<PAGE>

PhageTx  shall be free to utilize the results of the  Services  described  under
this Agreement without any further payment or obligation to Advisor. Thus, it is
also  essential  that  Advisor  shall  undertake  not to disclose to PhageTx any
information  which is secret or  confidential  or  belonging  to Advisor or to a
third party,  or with respect to which Advisor is under an obligation to a third
party to maintain  confidentiality.  Similarly, if during this Agreement Advisor
discloses any  inventions to PhageTx which were  conceived  prior to the term or
are outside the scope of the Services under this  Agreement,  PhageTx shall have
no liability to Advisor because of its use of such ideas, except that this shall
not be  construed as a license  under any valid  patent now or hereafter  issued
thereon.

7.  Publicity - Advisor shall not originate any  publicity,  news  releases,  or
other  public  announcement,  written or oral,  whether  to the public  press or
otherwise,   relating  to  this  Agreement,  to  any  amendment  hereto,  or  to
performance hereunder without PhageTx's prior written consent.

8.  Conflict  of Interest - Advisor  represents  that he is  presently  under no
obligation  to  any  third  party   (including  a  prior  employer,   government
organization,  and others  with whom he may now  consult  or may have  consulted
previously)  which would  prevent his  carrying  out his duties and  obligations
under this  Agreement or which is  inconsistent  with the  provisions  contained
herein. To avoid any potential  conflict of interest,  Advisor agrees to provide
written notice to PhageTx  within one (1) week of entering into any  consulting,
advisory or  research  agreement  with a  corporate  third party in the field of
bacteriophage  technology  or products  during the period  Advisor is  providing
Services to PhageTx.  The term  "Corporate" is intended to mean any organization
operating  in the  United  States of  America  or in a foreign  country  with an
expressed  intent  to make  profits  and  includes  organizations  like  limited
partnerships, joint ventures, corporations, and the like.

9. Freedom of Action - It is agreed that  Advisor's  rendering of services under
this  Agreement  shall  in no  way  conflict  or  interfere  with  his  existing
professional responsibilities. In that Advisor is an independent contractor, and
not an employee of PhageTx,  PhageTx shall not be responsible for Advisor's acts
while  Advisor is  performing  the  Services  hereunder,  whether  on  PhageTx's
premises  or  elsewhere,  and  Advisor  shall not have  authority  to speak for,
represent,  or obligate  PhageTx in any way without the explicit  prior  written
authority from PhageTx.

If any part of this Agreement shall be held as  unenforceable,  the remainder of
the  Agreement  shall  nevertheless  remain  in full  force and  effect  and the
unenforceable  provision  shall be construed by the court in such a manner as to
be held enforceable while giving maximum effect to the intended meaning.

Please indicate  Advisor's  acceptance  of the  foregoing  by  returning a fully
executed copy of this Agreement to PhageTx.

Phage Therapeutics, Inc.:                            Advisor:

19017 - 120th Avenue Ne, Suite 102                   John J. Majnarich, PhD

Bothell, WA 98011                                    4785 - 308th Avenue SE

                                                     Preston, WA 98050

By: /s/ Richard C. Honour /s/                    By: /s/ John J. Majnarich /s/
    -------------------------                        -------------------------
Richard C. Honour, PhD                           John J. Majnarich, PhD

President & CEO                                  Advisor

Date: 02.09.01                                    Date:  2/08/01
      --------                                          ---------

<PAGE>

                               ADVISORY AGREEMENT

Phage  Therapeutics,  Inc.  ("PhageTx" or the  "Company")  desires to engage the
advisory  services  ("Services")  of  Michael  C.  Maloney,  RAC,  as an advisor
("Advisor")  in the general  field of  Regulatory  Affairs.  Advisor  desires to
provide such Services to PhageTx.  By execution of this Advisory  Agreement (the
"Agreement"), and Advisor agrees to provide such Services in accordance with the
following terms and conditions:

1.  Services - At times  mutually  agreeable  to  Advisor  and  PhageTx,  and as
requested by PhageTX, Advisor will undertake the designated Services for one (1)
year,  commencing on the effective date of this Agreement (See Section 4 below).
It is expected that Advisor will provide at least twelve (12) days of cumulative
Services  during  the one (1)  year  period  of this  Agreement,  consisting  of
periodic  teleconferences,   electronic  mail,  written  communications,  direct
meetings, and the like, upon the prior agreement of Advisor and PhageTx.

2.  Compensation - In recognition  of Advisor's  contributions  to the Company's
product  development  efforts,  PhageTx  wishes  Advisor to  participate  int eh
Company's  future success by granting to Advisor an option to purchase shares of
stock in the Company in accord with the legal terms and  conditions of the Phage
Therapeutics, Inc. Stock Option Plan. The grant of options will be determined by
the Board of Directors,  which  functions as  Administrator  of the Stock Option
Plan, and will be executed through a separate Stock Option Agreement.

3. Independent Contractor - It is agreed that Advisor will have complete freedom
of action as to the details,  methods, and means of performing the Services.  It
is further  understood  that Advisor is retained and has contracted with PhageTx
only for the  purposes and to the extent set forth in this  Agreement,  and that
Advisor's  relation to PhageTx during the period of this Agreement shall be that
of an independent contractor,  and that Advisor shall be free to dispose of such
portion of his entire time, energy and skill as he is not obligated to devote to
PhageTx in such manner as he sees fit and to such person, firms, or corporations
as he deems  necessary,  so long as same does not create a conflict  of interest
between PhageTx and such other persons, firms or corporations. Advisor shall not
be considered  under the provisions of this Agreement or otherwise as having the
status of an employee of PhageTx,  nor shall  Advisor be entitled  hereafter  to
participate in any plans,  arrangements or  distributions by PhageTx relating to
any  pension,  deferred  compensation,   bonus,  stock  bonus,  hospitalization,
insurance  or  other  benefits  extended  to its  employees,  since  Advisor  is
performing the Services as an independent contractor.

4. Effective  Date,  Term,  Termination  and Extension - This Agreement  becomes
effective on January 1, 2001,  and will  continue in effect  until  December 31,
2001 (the first  twelve-month-period).  It is  provided,  however,  that  either
Advisor or PhageTx may terminate  this  Agreement at any time during its term by
giving at least one (1) month written notice to the other. At the sole option of
PhageTx,  this Agreement may be extended for one (1) or more consecutive  twelve
(12)-month  period(s),  under similar terms as are provided herein, by PhageTx's
providing to Advisor  written notice of its desire to continue the Agreement for
an  additional  term by at least two (2)  months  prior to the end of the twelve
(12)-month period in question.  However, certain of the terms may be modified by
mutual agreement of the parties.

5.  Inventions  - During  Advisor's  Service to PhageTx,  PhageTx  may  disclose
certain  confidential  information to Advisor and may ask Advisor to participate
in activities that may result in inventions  related to PhageTx's  technology or
business.  To the  extent  that  Advisor  is not  precluded  from  doing so by a
pre-existing employment contract or another agreement, where, as a direct result
of such  Services  to PhageTx,  Advisor  receives or is made aware of techn ical
information by a PhageTx employee, consultant, advisor or contractor that causes
Advisor to  conceive,  make or develop  any  inventions  relating  to  PhageTx's
bacteriophage  technology or products,  Advisor's  signature hereon notices that
Advisor agrees to: a) give notice of any such invention to PhageTx; b) assign to
PhagTx  all of  Advisor's  rights  therein,  in-so-far  as those  rights are not
subject to conditions of Advisor's current employment or another agreement; and,
c) execute any  documents  and otherwise  reasonably  cooperate  with PhageTx in
securing patents on such inventions.

6. Security - Advisor  shall,  during and  subsequent  to providing  Services to
PhageTx,  keep confidential and shall not use any technical or other proprietary
information  provided  by  PhageTx,  including  knowledge  of PhageTx  projects,
general  activities and proprietary  information not publicly disclosed relating
to PhageTx's  technology,  products and business  which Advisor may acquire as a
result of the Services or otherwise.  Advisor shall hold all such information in
strict  confidence and shall not use or disclose such information in any manner,
or cause same to be published  without  PhageTx's  prior written  consent.  This
obligation of confidence has been agreed to and is provided for between  Advisor
and PhageTx in a separate  Confidential  Disclosure  Agreement  executed by both
parties on October 16, 2000
           -----------------

<PAGE>

PhageTx  shall be free to utilize the results of the  Services  described  under
this Agreement without any further payment or obligation to Advisor. Thus, it is
also  essential  that  Advisor  shall  undertake  not to disclose to PhageTx any
information  which is secret or  confidential  or  belonging  to Advisor or to a
third party,  or with respect to which Advisor is under an obligation to a third
party to maintain  confidentiality.  Similarly, if during this Agreement Advisor
discloses any  inventions to PhageTx which were  conceived  prior to the term or
are outside the scope of the Services under this  Agreement,  PhageTx shall have
no liability to Advisor because of its use of such ideas, except that this shall
not be  construed as a license  under any valid  patent now or hereafter  issued
thereon.

7.  Publicity - Advisor shall not originate any  publicity,  news  releases,  or
other  public  announcement,  written or oral,  whether  to the public  press or
otherwise,   relating  to  this  Agreement,  to  any  amendment  hereto,  or  to
performance hereunder without PhageTx's prior written consent.

8.  Conflict  of Interest - Advisor  represents  that he is  presently  under no
obligation  to  any  third  party   (including  a  prior  employer,   government
organization,  and others  with whom he may now  consult  or may have  consulted
previously)  which would  prevent his  carrying  out his duties and  obligations
under this  Agreement or which is  inconsistent  with the  provisions  contained
herein. To avoid any potential  conflict of interest,  Advisor agrees to provide
written notice to PhageTx  within one (1) week of entering into any  consulting,
advisory or  research  agreement  with a  corporate  third party in the field of
bacteriophage  technology  or products  during the period  Advisor is  providing
Services to PhageTx.  The term  "Corporate" is intended to mean any organization
operating  in the  United  States of  America  or in a foreign  country  with an
expressed  intent  to make  profits  and  includes  organizations  like  limited
partnerships, joint ventures, corporations, and the like.

9. Freedom of Action - It is agreed that  Advisor's  rendering of services under
this  Agreement  shall  in no  way  conflict  or  interfere  with  his  existing
professional responsibilities. In that Advisor is an independent contractor, and
not an employee of PhageTx,  PhageTx shall not be responsible for Advisor's acts
while  Advisor is  performing  the  Services  hereunder,  whether  on  PhageTx's
premises  or  elsewhere,  and  Advisor  shall not have  authority  to speak for,
represent,  or obligate  PhageTx in any way without the explicit  prior  written
authority from PhageTx.

If any part of this Agreement shall be held as  unenforceable,  the remainder of
the  Agreement  shall  nevertheless  remain  in full  force and  effect  and the
unenforceable  provision  shall be construed by the court in such a manner as to
be held enforceable while giving maximum effect to the intended meaning.

Pleas  indicate  Advisor's  acceptance  of the  foregoing  by  returning a fully
executed copy of this Agreement to PhageTx.

Phage Therapeutics, Inc.:                            Advisor:

19017 - 120th Avenue Ne, Suite 102                   Michael C. Maloney

Bothell, WA 98011                                    16050 NE 165th St.

                                                     Woodinville, WA 98072

By: /s/ Richard C. Honour /s/                      By: /s/ Michael Maloney /s/
    -------------------------                          -----------------------
Richard C. Honour, PhD                             Michael Maloney

President & CEO                                    Advisor

Date: 02.09.01                                     Date:  2/09/01
      --------                                           ---------Exhibit 10.2

                        CONFIDENTIAL DISCLOSURE AGREEMENT
                        ---------------------------------

This agreement (the  "Agreement") is made effective on this date,  ____________,
by and between  Phage  Therapeutics,  Inc.,  19017 - 120th Avenue NE, Suite 102,
Bothel,  WA  98011  ("PhageTx")  and  ____________________   ("Recipient")  (the
"Parties") for  establishing  the conditions  under which PhageTx shall disclose
certain proprietary and confidential information ("Information") to Recipient.

         WHEREAS, PhageTx has entered into an Advisory Agreement with Recipient,
whereby Recipient will provide certain _________________ work, and

         WHEREAS,  Recipient is desirous of obtaining  certain  proprietary  and
confidential  Information  from  PhageTx,  including,  but not limited to, data,
know-how,   inventions,   discoveries,   products,   product  designs,   product
development  plans,  corporate  strategic  plans, or other business or financial
plans and information, in any form, whether written, oral, digital or otherwise,
in order to perform the said scientific work,

         THEREFORE,  in consideration of these stated mutual  understandings  by
PhageTx and Recipient, the Parties agree that:

(1)      Recipient shall keep as confidential  all proprietary and  confidential
         Information,  including  knowledge of PhageTx's  projects,  project and
         product  plans,   genomic  and  oligonucleotide,   sequences,   general
         activities and any other  proprietary and confidential  Information not
         publicly  disclosed,  as  may  be  related  to  PhageTx's  business  or
         technical  activities  which may be acquired as a result of disclosures
         by PhageTx's personnel or otherwise.

(2)      Recipient  shall not  disclose  PhageTx  proprietary  and  confidential
         Information to any third party without written authorization by PhageTx
         except as permitted herein.

(3)      Recipient's  dissemination  of  PhageTx  proprietary  and  confidential
         Information   shall  be   limited  to  those   colleagues,   employees,
         subcontractors or other professional  associates whose duties justify a
         need to know, and then only on basis of clear  understanding that these
         employees and professional associates are also under written obligation
         to  maintain  the  proprietary  and  confidential  status  or any  such
         Information so received and disseminated.

(4)      Recipient shall hold such proprietary and  confidential  Information in
         confidence  and shall not disclose such  proprietary  and  confidential
         Information  in any  manner,  or  cause  same to be  published  without
         PhageTx's prior written consent.

(5)      Recipient shall not use or allow to be used outside of the planned uses
         for the purpose of this  Agreement  any  proprietary  and  confidential
         Information  or any  biological  materials  provided  to  Recipient  by
         PhageTx under this Agreement.

(6)      The obligations of confidence and non-use shall not apply to:

          a)   Information  disclosed to Recipient by PhageTx which, at the time
               of  disclosure  to  Recipient,  is  published  or  already  known
               publicly or is otherwise in the public domain;

          b)   Information which, after it is disclosed to Recipient by PhageTx,
               is  published  or becomes  part of the public  domain  through no
               fault of Recipient;

          c)   Information  disclosed to Recipient by PhageTx which was known to
               Recipient  prior  to the  time of  disclosure,  as  evidenced  by
               Recipient's prior written records;

          d)   Information which has been or hereafter is disclosed to Recipient
               in good  faith by a third  party  not  under  any  obligation  of
               confidence  or secrecy to  PhageTx at the time of  disclosure  to
               Recipient; and

          e)   Information which is developed independently by Recipient without
               reference to PhageTx's proprietary and confidential Information.

<PAGE>

7)       Title to all proprietary and  confidential  Information,  including and
         new proprietary and confidential Information that is expected to result
         from the  scientific  work  contemplated  herein,  plus any  biological
         materials  and property  provided to Recipient by PhageTx  shall remain
         exclusively with PhageTx. No intellectual  property rights are granted,
         by implications or otherwise, by this Agreement,  and the disclosure of
         proprietary  and  confidential  Information  shall  not  result  in any
         obligations to grant any rights or licenses.  Upon request at any time,
         Recipient  shall  immediately  account  for and return to  PhageTx  all
         proprietary  and  confidential  information,   materials  and  property
         requested.

8)       The obligation of confidentiality under this Agreement shall terminate
         five (5) years after the  effective date of this Agreement.

9)       Recipient agrees not to originate any publicity,  news release or other
         public  announcement  written or oral,  whether to the public  press or
         otherwise,   relating  to  PhageTx,  without  PhageTx's  prior  written
         consent.

10)      This  Agreement  shall  be  governed  by  the  laws  of  the  State  of
         Washington,  and  constitutes  the  complete  and  exclusive  Agreement
         between the Parties.

Phage Therapeutics, Inc.:                   Recipient

By: /s/ Richard C. Honour, PhD  /s/         By: ______________________

Richard C. Honour                           Typed Recipients Name

Date:      _________                        Date:   ______________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}]]